Appointment of SVP for Tetris Pharma Ltd

Arecor Therapeutics PLC

03 January 2024

 

Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR APPOINTS DR HELEN PARRIS AS SENIOR VICE PRESIDENT, COMMERCIAL AND GENERAL MANAGER OF TETRIS PHARMA LTD

Cambridge, UK, 3 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, is pleased to announce the appointment of Dr. Helen Parris as Senior Vice President, Commercial and General Manager of the Group's subsidiary company, Tetris Pharma Ltd ("Tetris Pharma"), effective Monday 15 January 2024.

Helen has over 20 years of scientific, commercial and government affairs experience across several international biopharmaceutical companies and has been responsible for launching transformational products and shaping markets across large pharmaceutical and biotechnology companies. Prior to joining Tetris Pharma, Helen served as General Manager Northern Markets (UK, Netherlands and Nordics) at Albireo Pharma, Inc., which was acquired by Ipsen (Euronext: IPN; ADR: IPSEY) in March 2023, and where she played a key role in establishing and building the regional affiliate and launching the first product to market.

Previously, Helen held multiple positions at Gilead (NASDAQ: GILD), including Executive Director EMEA, Global Affairs Regional Lead, and was instrumental in broadening patient access to treatment. Whilst at Gilead, Helen led the launch of several transformational drugs, developed critical launch strategies and expanded commercial opportunities.

Helen holds a BSc in Biology from York University, a PhD from Leeds University and an MBA from Henley Management College.

Sarah Howell, Chief Executive Officer at Arecor, said: "I am delighted to welcome Helen to Tetris Pharma and the Arecor Group as a key member of our leadership team. Helen's proven track record in bringing products to market and growing sales will be key as we continue the roll-out of Ogluo® across the UK and Europe. Ogluo® is an important treatment for people with diabetes and their caregivers that can provide them with the confidence to manage severe hypoglycaemic events and, under Helen's leadership, Tetris Pharma is even better positioned for the continued adoption of this key product in a c.£100 million market. Not only will this deliver a revenue stream but a successful commercial distribution platform through Tetris Pharma is highly complementary to our existing specialty hospital products business and has significant growth potential, providing Arecor with the capability to take selected products to market in the UK and Europe."

 Dr. Helen Parris, Senior Vice President, Commercial and General Manager at Tetris Pharma, commented: "I am thrilled to be joining the team at Tetris Pharma to support the development of the company's lead product, Ogluo®, and continue its accelerated roll-out across Europe. Ogluo^® meets a key need for people living with diabetes at risk of severe hypoglycaemia, a condition which can have a profound effect on the everyday lives of those with diabetes and their caregivers. I look forward to leading the company as it continues to expand its pan-European presence."

-ENDS-

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: [phone] Email: [e-mail]
Susan Lowther, Chief Financial Officer	Tel: [phone] Email: [e-mail]
Mo Noonan, Communications	Tel: [phone] Email: [e-mail]
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: [phone]
ICR Consilium
Chris Gardner, David Daley, Lindsey Neville	Tel: [phone] Email: [e-mail]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com

 

END